Command Palette

Search for a command to run...

Clinical Trials · NCT04154072

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

CompletedPhase 2Exenatide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Neuraly, Inc.
Enrollment
255
Start date
Feb 2020
Locations
61 sites, United States, Canada
Primary endpoint
Change in Unified Parkinson's Disease Rating Scale in combined score of Parts II and III from baseline to 36 weeks
View Exenatide compound reference